Fitz‑Hugh–Curtis Syndrome – A Complete Medical Guide

Overview

Fitz‑Hugh–Curtis syndrome (FHCS) is a rare perihepatic inflammation that most commonly occurs as a complication of pelvic inflammatory disease (PID). It is characterized by infection‑related adhesions (scar tissue) between the liver capsule and the diaphragm or abdominal wall, producing sharp right‑upper‑quadrant (RUQ) pain.

• Typical population: Women of reproductive age (15‑45 years) who have a sexually transmitted infection (STI) such as chlamydia or gonorrhea. Men can rarely develop FHCS after disseminated gonococcal infection, but this is uncommon.
• Prevalence: Exact numbers are unknown because FHCS is often under‑diagnosed. Estimates suggest it occurs in 10‑30 % of women with acute PID, translating to roughly 1–3 cases per 10,000 women per year in the United States ¹.
• Why it matters: The intense RUQ pain can mimic gallbladder disease or hepatic pathology, leading to unnecessary surgery if not recognized.

Symptoms

The clinical picture of FHCS results from both the underlying PID and the perihepatic inflammation. Symptoms may appear days to weeks after the initial STI infection.

Typical Symptoms

• Sharp, stabbing RUQ or right‑subcostal pain: Often worsens with deep breathing, coughing, or movement (pleuritic quality).
• Lower abdominal / pelvic pain: Reflects concurrent PID (uterine, cervical, or tubal inflammation).
• Fever & chills: Low‑grade fever (≤38.5 °C) is common; high fevers suggest more severe infection.
• Vaginal discharge: Purulent or mucopurulent cervical discharge typical of chlamydia or gonorrhea.
• Dyspareunia (painful intercourse) and dysuria (painful urination): Result from PID.
• Nausea or loss of appetite: Secondary to abdominal pain.

Atypical / Less Common Signs

• Right‑shoulder pain (referred pain via phrenic nerve).
• Palpable “violin‑string” adhesions on laparoscopy (diagnostic hallmark).
• Absence of RUQ pain – some patients present only with PID symptoms, and FHCS is discovered incidentally.

Causes and Risk Factors

FHCS is not a disease in itself; it is a sequela of an existing infection.

Primary Causative Agents

• Chlamydia trachomatis – responsible for ~70 % of cases ².
• Neisseria gonorrhoeae – implicated in 20‑30 % of cases.
• Other less common organisms: Mycoplasma genitalium, Ureaplasma urealyticum, bacterial vaginosis‑associated bacteria, and rarely anaerobes in polymicrobial PID.

Risk Factors

• Multiple sexual partners or new partner within the past 6 months.
• Inconsistent condom use.
• Previous episode of PID or untreated STI.
• Female anatomy that facilitates ascending infection (shorter cervical canal, uterine fibroids, etc.).
• Immunocompromised state (HIV, immunosuppressive meds) – may worsen infection spread.

Diagnosis

Because FHCS mimics other abdominal conditions, a systematic approach is essential.

Clinical Evaluation

• Detailed sexual and medical history (STI exposure, recent PID, contraceptive use).
• Physical exam – tenderness in RUQ + pelvic tenderness; “Murphy’s sign” (inspiratory arrest on RUQ palpation) may be present but is not specific.

Laboratory Tests

• STI testing: Nucleic acid amplification tests (NAAT) for C. trachomatis and N. gonorrhoeae from cervical, urine, or urethral samples.
• Complete blood count (CBC) – may show leukocytosis.
• Inflammatory markers (CRP, ESR) – elevated but nonspecific.

Imaging Studies

• Ultrasound (RUQ): Usually normal; helps rule out gallstones, cholecystitis, or hepatic abscess.
• CT abdomen/pelvis with contrast: May reveal “violin‑string” adhesions, perihepatic fat stranding, or fluid collections.
• Magnetic resonance imaging (MRI): Provides superior soft‑tissue contrast; useful if CT contraindicated.

Laparoscopy (Gold Standard)

Diagnostic laparoscopy directly visualizes the characteristic thin, white adhesions (“violin‑string” fibrosis) between the liver capsule and diaphragm or anterior abdominal wall. It also allows simultaneous treatment (adhesiolysis) and sampling for culture if needed. Laparoscopy is reserved for cases where non‑invasive testing is inconclusive or when surgical emergencies cannot be excluded.

Treatment Options

Management targets the underlying STI, resolves inflammation, and relieves pain.

Antibiotic Therapy

Guidelines follow CDC’s PID treatment recommendations, adapted for FHCS.

• First‑line (outpatient):
  • Doxycycline 100 mg orally twice daily for 14 days plus
  • Azithromycin 1 g orally once (alternative if doxycycline contraindicated).
• If gonorrhea is confirmed or highly suspected: Add a single dose of ceftriaxone 250 mg IM (or 500 mg if weight ≥ 150 lb).
• Severe disease or inability to tolerate oral meds: Hospitalization with IV cefotaxime or ceftriaxone plus doxycycline, and possibly metronidazole for anaerobic coverage.
• Partner treatment is mandatory – the sexual partner(s) should receive the same regimen to prevent reinfection.

Pain Management

• Acetaminophen or NSAIDs (ibuprofen 400‑600 mg every 6 h) for mild‑moderate pain.
• Short course of opioids (e.g., hydrocodone/acetaminophen) only if pain is severe and not controlled with NSAIDs, and under close supervision.

Surgical / Procedural Interventions

• Laparoscopic adhesiolysis: Considered when adhesions cause persistent pain despite adequate antibiotic therapy (≈10‑15 % of cases). It provides symptom relief in 70‑80 % of patients ³.
• Drainage of any associated abscesses or tubo‑ovarian collections.

Lifestyle & Supportive Measures

• Complete sexual abstinence until treatment is finished and symptoms resolve.
• Hydration and balanced diet to support immune function.
• Stress reduction (mind‑body techniques, adequate sleep) can improve pain tolerance.

Living with Fitz‑Hugh–Curtis Syndrome

Even after the infection clears, some patients experience lingering discomfort or anxiety about recurrence. Below are practical tips for daily life.

• Follow‑up appointments: See your healthcare provider 1–2 weeks after completing antibiotics to confirm symptom resolution and negative STI tests.
• Pelvic health: Consider a referral to a gynecologist or pelvic health physical therapist for pelvic floor strengthening, which may reduce chronic pelvic pain.
• Exercise: Low‑impact activities (walking, swimming, yoga) maintain fitness without stressing the RUQ area. Avoid heavy lifting or intense core workouts for at least 2 weeks post‑treatment.
• Heat therapy: Warm compresses on the RUQ for 15 minutes can ease residual soreness.
• Contraception: Use barrier methods (condoms) or long‑acting reversible contraceptives (IUD, implant) to diminish future STI risk.
• Mental health: Persistent pain can be distressing; counseling or support groups for PID‑related conditions can be beneficial.

Prevention

Because FHCS is almost always a sequel of an STI, primary prevention of chlamydia and gonorrhea dramatically lowers risk.

• Regular STI screening: Annual testing for sexually active women under 25, and at any time after new or multiple partners (CDC recommendation ⁴).
• Consistent condom use: Properly used latex or polyurethane condoms reduce STI transmission by ~85 %.
• Vaccination: The HPV vaccine does not prevent chlamydia/gonorrhea but protects against cervical cancer, which can coexist with PID.
• Prompt treatment of genital infections: Early antibiotics stop the ascending spread.
• Partner notification: Ensure sexual partners are tested and treated.
• Limit alcohol & tobacco: These substances impair immune response and increase susceptibility to infection.

Complications

If left untreated, FHCS can lead to serious health issues.

• Chronic RUQ pain: Persistent adhesions may cause ongoing discomfort.
• Infertility: Ongoing PID can scar the fallopian tubes (hydrosalpinx), reducing fertility potential.
• Abscess formation: Tubo‑ovarian or hepatic subcapsular abscesses may require drainage.
• Peritonitis: Rare but possible if infection spreads to the peritoneal cavity.
• Increased risk of ectopic pregnancy: Scarring of the tubes raises the chance of implantation outside the uterus.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, Cleveland Clinic, American College of Obstetricians and Gynecologists (ACOG), peer‑reviewed journals (e.g., AJOG, Obstetrics & Gynecology).